Eli Lilly and Company v Apotex Pty Ltd

Link copied
Case Copied 5 min read

FEDERAL COURT OF AUSTRALIA

Eli Lilly and Company v Apotex Pty Ltd [2014] FCA 381

Citation: Eli Lilly and Company v Apotex Pty Ltd [2014] FCA 381
Parties: ELI LILLY AND COMPANY and ELI LILLY AUSTRALIA PTY LIMITED (ACN 000 233 992) v APOTEX PTY LTD (ACN 096 916 148) and APOTEX PTY LTD (ACN 096 916 148) v ELI LILLY AND COMPANY 
File number: NSD 622 of 2012
Judge: NICHOLAS J
Date of judgment: 10 April 2014
Legislation: Evidence Act1995 (Cth) s 192A
Federal Court Rules 2011 (Cth) r 34.50
Date of hearing: 4 April 2014
Date of publication of reasons: 16 April 2014
Place: Sydney
Division: GENERAL DIVISION
Category: No catchwords
Number of paragraphs: 11
Counsel for the Applicants: Mr AR Lang
Solicitor for the Applicants: Wrays Lawyers
Counsel for the Respondent: Mr DK Catterns QC
Solicitor for the Respondent: Herbert Smith Freehills

IN THE FEDERAL COURT OF AUSTRALIA

NEW SOUTH WALES DISTRICT REGISTRY

GENERAL DIVISION

NSD 622 of 2012

BETWEEN:

ELI LILLY AND COMPANY
First Applicant

ELI LILLY AUSTRALIA PTY LIMITED (ACN 000 233 992)
Second Applicant

AND:

APOTEX PTY LTD (ACN 096 916 148)
Respondent

AND BETWEEN:

APOTEX PTY LTD (ACN 096 916 148)
Cross-Claimant

AND:

ELI LILLY AND COMPANY
Cross-Respondent

JUDGE:

NICHOLAS J

DATE OF ORDER:

10 APRIL 2014

WHERE MADE:

SYDNEY

THE COURT ORDERS THAT:

1.Leave is given to the applicants pursuant to rule 34.50 to rely upon the evidence of the experiments referred to in section F9 and section G of the affidavit of Shen Yung Luk sworn 10 March 2014 (Dr Luk’s evidence).

2.Order 1 is made without prejudice to the respondent’s right to raise any other objection to the admissibility of Dr Luk’s evidence apart from that which was taken in reliance upon rule 34.50.

3.The costs of both interlocutory applications are to be the respondent’s costs in the proceeding.

Note:Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.


IN THE FEDERAL COURT OF AUSTRALIA

NEW SOUTH WALES DISTRICT REGISTRY

GENERAL DIVISION

NSD 622 of 2012

BETWEEN:

ELI LILLY AND COMPANY
First Applicant

ELI LILLY AUSTRALIA PTY LIMITED (ACN 000 233 992)
Second Applicant

AND:

APOTEX PTY LTD (ACN 096 916 148)
Respondent

AND BETWEEN:

APOTEX PTY LTD (ACN 096 916 148)
Cross-Claimant

AND:

ELI LILLY AND COMPANY
Cross-Respondent

JUDGE:

NICHOLAS J

DATE:

10 APRIL 2014

PLACE:

SYDNEY

REASONS FOR JUDGMENT

  1. The substantive proceeding involves a claim by the applicant for patent infringement.  The patent in suit is the same patent that was referred to in Eli Lilly and Company v Generic Health Pty Ltd [2013] FCA 1254. Both proceedings are fixed for hearing commencing on 2 June 2014.

  2. A key issue in the infringement case concerns the size of raloxifene particles in the respondent’s tableted products. Considerable time and effort has been spent by the parties over many months attempting to agree upon an appropriate protocol that would form the basis for experimental evidence directed to that issue. The…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Eli Lilly and Company v Apotex Pty Ltd and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2014] FCA 381
Decision Date

CaseChat Overview and Summary

Eli Lilly and Company and Eli Lilly Australia Pty Limited brought an action against Apotex Pty Ltd for alleged patent infringement. The case revolves around the size of raloxifene particles in the respondent's tableted products, with both parties having spent considerable time attempting to agree on an appropriate experimental protocol. This protocol was finally agreed upon and experiments were conducted in England. The court was required to decide whether the applicants could rely on specific sections of an affidavit sworn by Dr Shen Yung Luk. The respondent argued that certain parts of Dr Luk’s evidence were inadmissible, specifically those related to the use of "Image J" software and the "Aggregate Experiment." The court found that the applicants should be granted leave to rely on the evidence in section F9 of Dr Luk’s affidavit, as the agreed protocol did not preclude further analysis of the digital images. Regarding the evidence in section G of Dr Luk’s affidavit, which involved additional sonication not provided for in the agreed protocol, the court allowed its use but noted that the relevance and reliability of this additional analysis remain to be explored. The court granted leave to the applicants to use the specified sections of Dr Luk’s affidavit while emphasizing that the weight to be given to this evidence would be determined at the trial. The costs of the interlocutory applications were to be borne by the respondent.

Orders

Orders of the court

Background

Background to the litigation

Evidence

Evidence Before The Court

Decision

Reasons for decision

Ratio Decidendi

Legal Principle Established